个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Qin, S.[1] * ; Cai, J-Q.[2] ; Li, E.[3] ; Xing, B.[4] ; Zhao, L.[5,6] ; Dai, C.[7] ; Li, J.[8] ; Shen, Y.[9] ; Chen, Z.[10] ; Liu, L.[11] ; Lu, Z.[12] ; Zang, A.[13] ; Bai, Y.[14] ; Liang, H.[15] ; Liang, J.[16,17] ; Liu, X.[18] ; Wang, J.[19,20] ; Chen, M-H.[21] ; Miao, R.[22] ; Qu, X.[22] ;
机构： [1]Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Canc Hosp,Dept Hepatobiliary Surg, Beijing, Peoples R China [3]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Shaanxi, Peoples R China [4]Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Hepatopancreatobiliary Surg Dept 1, Beijing, Peoples R China [5]Shandong Canc Hosp, Dept Hepatobiliary Surg, Jinan, Shandong, Peoples R China [6]Inst Shandong First Med Univ & Shandong Acad Med, Jinan, Shandong, Peoples R China [7]China Med Univ, Dept Hepatobiliary & Splen Surg, Shengjing Hosp, Shenyang, Peoples R China [8]Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Peoples R China [9]Zhejiang Univ, Sch Med, Div Hepatobiliary & Pancreat Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China [10]Anhui Med Univ, Affiliated Hosp 2, Dept Med Oncol, Hefei, Peoples R China [11]Univ Sci & Technol China, Dept Hepatobiliary Surg, Anhui Prov Key Lab Hepatopancreatobiliary Surg, Div Life Sci & Med,Affiliated Hosp USTC 1, Hefei, Peoples R China [12]Bengbu Med Coll, Affiliated Hosp 1, Dept Hepatobiliary Surg, Bengbu, Peoples R China [13]Hebei Univ,Affiliated Hosp,Dept Med Oncol,Baoding,Peoples R China [14]Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China [15]Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China [16]Shandong First Med Univ, Affiliated Hosp 1, Dept Oncol, Jinan, Peoples R China [17]Shandong Prov Qianfoshan Hosp, Shandong Key Lab Rheumat Dis & Translat Med, Shandong Lung Canc Inst, Jinan, Peoples R China [18]Jinling Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Peoples R China [19]Zhengzhou Univ, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Peoples R China [20]Henan Canc Hosp, Zhengzhou, Peoples R China [21]Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan [22]AstraZeneca, R&D, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.09.1391
ISSN：
基金：
AstraZeneca
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
推荐引用方式(GB/T 7714)：
Qin S.,Cai J-Q.,Li E.,et al.Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study[J].ANNALS OF ONCOLOGY.2023,34:S216-S217.doi:10.1016/j.annonc.2023.09.1391.
APA：
Qin, S.,Cai, J-Q.,Li, E.,Xing, B.,Zhao, L....&Qu, X..(2023).Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study.ANNALS OF ONCOLOGY,34,
MLA：
Qin, S.,et al."Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study".ANNALS OF ONCOLOGY 34.(2023):S216-S217

资源点击量：15101 今日访问量：3 总访问量：963 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号